FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * High Katherine A   2. Issuer Name and Ticker or Trading Symbol Spark Therapeutics, Inc. [ONCE] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) See Remarks (Last) (First) (Middle) C/O SPARK THERAPEUTICS, INC., 3737 MARKET STREET, SUITE 1300 3. Date of Earliest Transaction (Month/Day/Year) 03/21/2019 (Street) PHILADELPHIA, PA 19104 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 03/21/2019   M   73,249 A $ 3.45 287,717 D   Common Stock 03/21/2019   F   31,653 D $ 113.25 256,064 D   Common Stock 03/21/2019   M   5,840 A $ 68.45 261,904 D   Common Stock 03/21/2019   M   3 A $ 40.44 261,907 D   Common Stock 03/21/2019   M   64,160 A $ 68.45 326,067 D   Common Stock 03/21/2019   F   49,561 D $ 113.255 276,506 D   Common Stock 03/21/2019   M   21,247 A $ 40.44 297,753 D   Common Stock 03/21/2019   F   25,993 D $ 113.26 271,760 D   Common Stock 03/21/2019   M   15,750 A $ 56.17 287,510 D   Common Stock 03/21/2019   F   11,184 D $ 113.26 276,326 D   Common Stock 03/21/2019   M   7,875 A $ 50.55 284,201 D   Common Stock 03/21/2019   F   5,367 D $ 113.26 278,834 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$ 3.45	03/21/2019		M			73,249	(1)	07/02/2024	Common Stock	73,249	$ 0	0	D
Stock Option (right to buy)	$ 68.45	03/21/2019		M			5,840	(2)	03/15/2025	Common Stock	5,840	$ 0	64,160	D
Stock Option (right to buy)	$ 40.44	03/21/2019		M			3	(3)	01/04/2026	Common Stock	3	$ 0	54,997	D
Stock Option (right to buy)	$ 68.45	03/21/2019		M			64,160	(2)	03/15/2025	Common Stock	64,160	$ 0	0	D
Stock Option (right to buy)	$ 40.44	03/21/2019		M			41,247	(3)	01/04/2026	Common Stock	41,247	$ 0	13,750	D
Stock Option (right to buy)	$ 56.17	03/21/2019		M			15,750	(4)	01/17/2027	Common Stock	15,750	$ 0	15,750	D
Stock Option (right to buy)	$ 50.55	03/21/2019		M			7,875	(5)	01/17/2028	Common Stock	7,875	$ 0	23,625	D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
High Katherine A C/O SPARK THERAPEUTICS, INC. 3737 MARKET STREET, SUITE 1300 PHILADELPHIA, PA 19104	X		See Remarks

Signatures

/s/ Joseph W. La Barge, attorney-in-fact for Katherine A. High		03/25/2019
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	25% vested on May 24, 2015, and the remainder vested in equal quarterly installments over the following three years.
(2)	25% vested March 16, 2016 and the remainder vested in equal quarterly installments over the following three years.
(3)	25% vested Jamuary 5, 2017 and the remainder vests in equal quarterly installments over the following three years.
(4)	25% vested January 18, 2018 and the remainder vests in equal quarterly installments over the following three years.
(5)	25% vested January 18, 2019 and the remainder vests in equal annual installments over the following three years.
Remarks: President and Head of Research and Development

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.